Zacks: Brokerages Set $90.00 Price Target for BioSpecifics Technologies Corp. (NASDAQ:BSTC)

BioSpecifics Technologies Corp. (NASDAQ:BSTC) has earned an average broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a strong buy rating.

Analysts have set a 12-month consensus target price of $90.00 for the company and are expecting that the company will post $0.94 EPS for the current quarter, according to Zacks. Zacks has also assigned BioSpecifics Technologies an industry rank of 56 out of 255 based on the ratings given to its competitors.

A number of research analysts have weighed in on BSTC shares. Zacks Investment Research cut shares of BioSpecifics Technologies from a “buy” rating to a “hold” rating in a research note on Friday, October 25th. HC Wainwright set a $90.00 target price on shares of BioSpecifics Technologies and gave the company a “buy” rating in a research note on Friday, October 11th. ValuEngine upgraded shares of BioSpecifics Technologies from a “sell” rating to a “hold” rating in a research note on Friday, October 4th. Finally, BidaskClub cut shares of BioSpecifics Technologies from a “sell” rating to a “strong sell” rating in a research note on Thursday, October 17th.

BSTC stock traded up $0.06 during midday trading on Tuesday, hitting $53.03. The stock had a trading volume of 30,400 shares, compared to its average volume of 57,895. BioSpecifics Technologies has a 1-year low of $45.81 and a 1-year high of $73.31. The firm has a market cap of $388.77 million, a P/E ratio of 19.42 and a beta of 1.16. The business has a fifty day moving average price of $50.45 and a two-hundred day moving average price of $57.46.

BioSpecifics Technologies (NASDAQ:BSTC) last released its earnings results on Friday, November 8th. The biopharmaceutical company reported $0.85 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.10. The firm had revenue of $9.44 million for the quarter, compared to analysts’ expectations of $8.86 million. BioSpecifics Technologies had a net margin of 64.23% and a return on equity of 21.82%. Analysts predict that BioSpecifics Technologies will post 3.27 EPS for the current fiscal year.

In other BioSpecifics Technologies news, Director Toby Wegman sold 1,100 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $55.23, for a total value of $60,753.00. Following the transaction, the director now directly owns 1,890 shares in the company, valued at $104,384.70. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 16.39% of the stock is owned by insiders.

Several hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC lifted its stake in shares of BioSpecifics Technologies by 140.1% during the 3rd quarter. Tower Research Capital LLC TRC now owns 485 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 283 shares in the last quarter. Eagle Asset Management Inc. lifted its stake in shares of BioSpecifics Technologies by 2.0% during the 3rd quarter. Eagle Asset Management Inc. now owns 61,090 shares of the biopharmaceutical company’s stock valued at $3,269,000 after buying an additional 1,206 shares in the last quarter. Monarch Partners Asset Management LLC lifted its stake in shares of BioSpecifics Technologies by 13.4% during the 3rd quarter. Monarch Partners Asset Management LLC now owns 8,536 shares of the biopharmaceutical company’s stock valued at $457,000 after buying an additional 1,010 shares in the last quarter. SG Americas Securities LLC purchased a new stake in shares of BioSpecifics Technologies during the 3rd quarter valued at approximately $645,000. Finally, Russell Investments Group Ltd. lifted its stake in shares of BioSpecifics Technologies by 225.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 53,683 shares of the biopharmaceutical company’s stock valued at $2,878,000 after buying an additional 37,212 shares in the last quarter. Institutional investors own 58.93% of the company’s stock.

BioSpecifics Technologies Company Profile

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for various indications in the United States and internationally. The company offers injectable collagenase for the treatment of Dupuytren's contracture and Peyronie's disease under the XIAFLEX or Xiapex brands.

Featured Article: What is the Quick Ratio?

Get a free copy of the Zacks research report on BioSpecifics Technologies (BSTC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioSpecifics Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSpecifics Technologies and related companies with MarketBeat.com's FREE daily email newsletter.